BioMarin Pharmaceutical Inc.

Mr. Bienaimé joined BioMarin in May 2005 as chief executive officer and member of the board of directors, bringing with him over 25 years of experience in the biotechnology and pharmaceutical industries. Under his leadership, the market capitalization of BioMarin went from around $450 million in May 2005 to over $3.5 billion in May 2008. BioMarin 2008 revenues around $300 million and is a fully integrated biopharmaceutical company with over 700 employees. From November 2002 to April 2005, Mr. Bienaimé served as chairman, chief executive officer, and president of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. Under his leadership, Genencor's revenues increased substantially to over $400 million and shareholder value increased dramatically, culminating in the sale of the company to Danisco in the spring of 2005 for an enterprise value of over $1.2 billion. From 1998 to late 2002, Mr. Bienaimé served as chairman, chief executive officer and president of Sangstat Medical Corporation, an immunology-focused biotechnology company that he guided to profitability prior to its acquisition by Genzyme Corporation. From 1992 to 1998, Mr. Bienaimé held several senior management positions at Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis), culminating in the position of senior vice president of worldwide marketing and business development responsible for, among other things, the launch of Lovenox® (for the prevention of pulmonary embolism and treatment of unstable angina) in the United States and Taxotere® (for breast and lung cancer) worldwide. Earlier in his career, he worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks. Mr. Bienaimé is chairman of the board of directors of NeurogesX, Inc., a member of the board of directors of Ensemble Discovery Corporation, and is a member of the advisory board of Bellevue Asset Management's BioVentures II fund. He received an M.B.A from the Wharton School at the University of Pennsylvania and an undergraduate degree in economics from the Ecole Superieure de Commerce de Paris.

BioMarin recently welcomed Dr. Henry Fuchs as Senior Vice President and Chief Medical Officer. Previously he served as Executive Vice President and Chief Medical Officer of Onyx Pharmaceuticals. He served as a director of Ardea Biosciences beginning in November 2001 and as its Chief Executive Officer from January 2003 until June 2005. Dr. Fuchs first joined Ardea as Vice President, Clinical Affairs in October 1996 and was appointed President and Chief Operating Officer in November 2001. From 1987 to 1996, Dr. Fuchs held various positions at Genentech where, among other responsibilities, he led the clinical program that resulted in the approval of Genentech’s Pulmozyme. Dr. Fuchs was also responsible for the Phase III development program that led to the approval of Herceptin to treat metastatic breast cancer. Dr. Fuchs received an M.D. degree from George Washington University and a B.A. degree in biochemical sciences from Harvard University.

Mr. Cooper joined BioMarin in October 2003 as vice president, controller, and was promoted to the position of chief financial officer in August 2005. Prior to BioMarin, he served as vice president of finance at Matrix Pharmaceutical where he worked for six years. Earlier in his career, Mr. Cooper held numerous finance-related positions within the health care and pharmaceutical industries, including corporate controller at Foundation Health Systems and director of business analysis at Syntex Corporation, a company he worked for from 1983 to 1995. Mr. Cooper, a certified public accountant, earned a B.A. in economics from the University of California, Los Angeles, and an M.B.A. from Santa Clara University.

Dr. Ramelmeier joined BioMarin in September 2006 as Vice President of Manufacturing and Process Development. His responsibilities include oversight of manufacturing, manufacturing sciences, process development, and facilities. Prior to joining BioMarin, Dr. Ramelmeier was vice president, Process Sciences, of the Global Biologics Supply Chain (formerly Centocor Inc.) at Johnson & Johnson. In this role, he oversaw technical support of J&J's BioPharm manufacturing plants, including process validation and tech transfer of new and existing products, regulatory inspections, and process improvements. From 2001 to 2005, he served as Executive Director, Pharmaceutical Development at Centocor, where he was responsible for pilot plant operations, clinical and toxicology supplies, and pilot-scale process development. In this role, his team increased clinical manufacturing capacity three-fold and developed scale-up capability to meet the growing needs of the BioPharm business in J&J. Earlier in his career, Dr. Ramelmeier was Senior Research Fellow, Bioprocess Research and Development at Merck & Co. Dr. Ramelmeier received his Ph.D. degree in Chemical Engineering at the University of California, Berkeley, and a B.S. degree in Chemical Engineering from Johns Hopkins University.

Ms. Waterhouse joined BioMarin in January 2000 and currently serves as vice president, Regulatory and Government Affairs. Her responsibilities include oversight of the worldwide regulatory and governmental strategies for all BioMarin products, including Aldurazyme® (laronidase) for MPS I and Naglazyme® (galsulfase) for MPS VI, both which were granted marketing authorization under her leadership. Prior to coming to BioMarin, Ms. Waterhouse was head of Regulatory Affairs at Onyx Pharmaceuticals where she managed worldwide regulatory activities for viral therapies in development for the treatment of oncology indications and served as primary contact with all regulatory agencies regarding preclinical, clinical and CMC aspects of product development. From 1991 to 1995, she served in a variety of roles at Celtrix Pharmaceuticals pertaining to quality assurance, clinical research and regulatory affairs. Ms. Waterhouse holds a B.S. in Biology from San Francisco State University and has completed numerous professional development courses. She is a member of the Drug Information Association and the Regulatory Affairs Professionals Society.

Dr. Baffi joined BioMarin in May 2000 and currently serves as senior vice president of technical operations responsible for overseeing the company’s manufacturing, process development, quality, compliance and analytical chemistry departments. From 1986 to 2000, Dr. Baffi served in a number of increasingly responsible positions at Genentech, primarily in the functional area of quality control. Prior to Genentech, Dr. Baffi worked for Cooper BioMedical as a research scientist and at Becton Dickinson Research Center as a post-doctoral fellow. Dr. Baffi has contributed to more than 20 regulatory submissions for product approval in the United States and Europe and to more than 50 regulatory submissions for investigational new drug testing. Dr. Baffi received a Ph.D, M.Phil and a B.S. in biochemistry from the City University of New York and an M.B.A. from Regis University.

Mr. Aselage joined BioMarin in July 2005 as Senior Vice President, Global Commercial Operations. Prior to joining BioMarin, Mr. Aselage held the position of Executive Vice President of Global Commercial Operations at Cell Therapeutics where he led efforts to streamline the company's United States and European commercial operations. Prior to Cell Therapeutics, Mr. Aselage served as Senior Vice President of North American Sales and Marketing for Genzyme Corporation following Genzyme's September 2003 acquisition of Sangstat Medical Corporation where he had worked since February 1999. While at Sangstat, Mr. Aselage restructured the company's sales, marketing and medical affairs groups and led the successful effort to make Thymoglobulin® the top selling product in its class. From 1996 through 1999, Mr. Aselage served as Director of Sales and Marketing at Advanced Tissue Sciences where he established the company's first sales and customer service groups. Earlier in his career, Mr. Aselage held a variety of sales and sales management positions at biotechnology and pharmaceutical companies including Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis), Genentech, Inc., and Bristol Laboratories. Mr. Aselage holds a Bachelor of Science degree in Biology from the University of Notre Dame.

Dr. O'Neill joined BioMarin Pharmaceutical Inc. in 2003 to lead Pharmacological Sciences. He oversees nonclinical development, including BioAnalytical Assay Research and Development, Assays Services, Pharmacology and Toxicology, and Clinical and Nonclinical Pharmacokinetics/Pharmacodynamics. From 1996 through 2003, Dr. O'Neill was a Senior Scientist/Scientist in the Toxicology Department at Genentech, Inc., a biotechnology company, where he led two nonclinical development efforts regarding Genentech's fibrinolytics, Activase™ and TNKase™, as well as the anti-angiogenic monoclonal antibody, Avastin™. Additionally, Dr. O'Neill contributed to the nonclinical development of Lucentis™ for the treatment of the neovascular form of age-related macular degeneration. Dr. O'Neill was a member of the Cardiovascular Therapeutic Area Team providing strategy and guidance regarding the development and in-licensing of cardiovascular molecules at Genentech and in this regard assessed over 30 opportunities for Genentech. Prior to Genentech, Dr. O'Neill was an Assistant Research Professor in the Division of Cardiovascular Medicine, Department of Internal Medicine, at the University of California, Davis where he investigated the role of reactive oxygen and nitrogen species during myocardial and limb ischemia and reperfusion. Currently, he is Assistant Adjunct Professor in the Pharmacology and Toxicology Graduate Group at UC Davis. Dr. O'Neill was a Postdoctoral Fellow at the National Institutes of Health, National Heart Lung and Blood Institute. Dr. O'Neill has contributed to 26 regulatory submissions in the US, EU, Australia and Japan and has coauthored over 40 peer-reviewed publications. Dr. O'Neill received his Ph.D. in Pharmacology and Toxicology from UC Davis in 1992 and has been a Diplomate of the American Board of Toxicology since 1995.

Mr. Maher joined BioMarin in August 2003. He is currently responsible for program management, and oversees all product development activities at BioMarin. From 1998 to 2003, Mr. Maher worked at Aradigm Corporation serving as vice president, program management. Prior to Aradigm, he served as director of clinical operations at Covance, Inc., and as vice president of operations at Spectra BioMedical, Inc. Prior to Spectra, Mr. Maher acted as director, therapeutics project management, at Chiron Corporation. Mr. Maher started his career at Genentech in 1981, serving in several capacities in manufacturing and process development, and finally as Manager of Product Development. Mr. Maher received a M.B.A. in health services management from Golden Gate University and a B.A. in biology from San Francisco State University.

Mr. Davis joined BioMarin in March 2004, and currently serves as vice president, general counsel and secretary. From 2000 to 2004, Mr. Davis worked in the San Francisco office of Paul Hastings Janofsky & Walker LLP, where he served on the firm's national securities practice committee. Mr. Davis has represented public and private companies and venture capital and investment banking firms in a wide range of corporate and securities matters, mergers and acquisitions, strategic alliance matters, and intellectual property-related business transactions. His experience involves a variety of industries, including biotechnology and life sciences. Mr. Davis received a B.A. in political economy from the University of California, Berkeley, and a J.D. from the University of San Francisco School of Law.

Dr. Gordon Vehar is the former Vice President of Research and Development for Raven Biotechnologies. He is the inventor of numerous biotechnology patents and the recipient of a collection of prestigious scientific awards including two Distinguished Inventor of the Year Awards from Intellectual Property Owners, Inc. Dr. Vehar also served in various roles throughout a 20-year tenure with Genentech, including Director of Cardiovascular Research and Staff Scientist for Cardiovascular Research and Protein Chemistry. Also at Genentech, he served as Project Team Leader on various drug discovery and development projects, which yielded four marketed products. He is the recipient of the Murray Thelin Award for Outstanding Research presented by the National Hemophilia Foundation, the Inventor of the Year Award given by Intellectual Property Owners, Inc., for the human tissue plasminogen activator (t-PA) patent for the treatment of heart attacks and stroke, and the Distinguished Inventor of the Year Award from Intellectual Property Owners, Inc. for the patent on recombinant Factor VIII, a genetically engineered clotting factor enabling production of a therapeutic product for treating hemophilia A. Dr. Vehar has served on the Scientific Advisory Board for the Oklahoma Center for Molecular Medicine, he is an inventor with 37 issued patents and is the author of more than 35 publications. Dr. Vehar received a Ph.D. from the University of Cincinnati Medical School.

Mr. Ajer joined BioMarin in September 2005 as vice president of Sales and Marketing Operations. He has over 20 years of experience in the pharmaceutical and biotech industry, with expertise in sales and marketing management, domestic and international business, and operational and corporate leadership. From November 2003 to August 2005, Mr. Ajer worked at Genzyme Corporation where he served most recently as vice president, Global Transplant Operations. In this role, Mr. Ajer developed capabilities and represented the business unit's objectives in numerous areas including long range planning, sales operations, global distribution and customer service, and global pricing and contracting. Prior to this, he served as senior director of Sales Operations, Bids and Contracts for SangStat Medical Corporation until the company's 2003 acquisition by Genzyme. From June 1986 to July 1999, Mr. Ajer held positions with increasing responsibility at ICN Pharmaceuticals, Inc., including director, Marketing and Sales Services, and director, Purchasing Worldwide. Mr. Ajer received both a B.S. in chemistry and an M.B.A. from the University of California, Irvine.

Mr. Grass joined BioMarin in 2002 and has 15 years of experience in biotechnology product development, finance and strategy. Mr. Grass is currently responsible for business and corporate development activities including product and technology licensing, acquisitions and corporate strategy. For two years prior to joining BioMarin, Mr. Grass was an associate at the investment bank Vrolyk & Company, focusing on mergers and acquisitions and private equity financings. Prior to that Mr. Grass was a research analyst at BioMedical Insights where he conducted strategic market research for established biopharmaceutical and emerging product development companies. Mr. Grass also worked in the biotechnology equity research group at SG Cowen between his first and second year of graduate studies in business. Mr. Grass started his career in biotechnology as a research scientist at Cerus Corporation where for five years he focused on research and development in the areas of cell biology and immunology. Mr. Grass holds a Bachelor of Science in biology from California Polytechnic State University in San Luis Obispo and an MBA in Finance from the University of Rochester in Rochester New York.

Mr. Chapman joined BioMarin as Vice President, Global Marketing in July 2007. Mr. Chapman is a seasoned marketing, sales and business development executive with over 30 years of experience in the biopharmaceutical and medical device industries. Most recently, 2004 through 2006 he was an officer of Alpha Innotech Corporation and served as Vice President Global Marketing and Sales. Under his leadership, revenue declines in previous years were reversed resulting in 10 consecutive quarters of double-digit growth. Mr. Chapman started his career in pharmaceuticals with Eli Lilly & Company. During his ten years there, he worked in field sales and progressed to home office assignments in marketing management and business development. From there Mr. Chapman moved into product management roles at Syntex (Naprosyn®) and then Genentech. As Activase® (t-PA), Product Manager, he led the global commercial launch of the largest biopharm product launch in the history of the industry up to that time; first year sales $187 million. Subsequently he held senior positions in start-up biotech and medical device companies and gained extensive experience marketing niche and specialty products. Mr. Chapman contributed to the formation of the marketing and sales departments at Triton Biosciences/Berlex Labs (Oncology/Immunology SBU). He was instrumental in helping the business unit grow from a research and development start-up to an operations-based enterprise with commercialized products. This included the successful introductions of Fludara® and Betaseron®, the latter setting another first year sales record of $206 million. In another career milestone, sales growth achieved at VidaMed under his leadership as VP Global Marketing and Sales resulted in its acquisition by Medtronic for $326 million in 2002. Mr. Chapman holds a B.S. in Biological Sciences from the University of California, Davis, and an M.B.A. from Southern Illinois University.

Dr. Bigornia joined BioMarin Pharmaceutical Inc. in February 2003 and currently serves as the Vice President of Intellectual Property (IP). She is responsible for the establishment and maintenance of an IP department, management of all company IP matters, the development and implementation of patent strategy for all company programs, and the provision of IP-related support to other departments within the company. Prior to joining BioMarin, Dr. Bigornia worked as Patent Counsel/Acting Director of IP for Hyseq Pharmaceutical (now Nuvelo) in Sunnyvale CA, and as a Patent Associate for Howrey, Simon, Arnold and White LLP in Menlo Park, CA. Dr. Bigornia received a J.D. from the University of San Diego School of Law and is a member of the California State Bar Association. She is registered to practice before the United States Patent and Trademark Office. Prior to her legal career, Dr. Bigornia received her doctoral degree in Pharmacology from the University of Manitoba in Canada and completed postdoctoral fellowships with the American Heart Association at the Albany Medical College in Albany, NY and with the National Institute of Health at the University of California, Davis. Dr. Bigornia has co-authored scientific publications in the areas of pharmacology and molecular virology.

Mr. Glass is BioMarin's Vice President and General Manager of European Operations. He has extensive international experience in pharmaceutical sales, marketing, and financial and regulatory management. Former General Manager for Altana/Nycomed, France, he also served as Managing Director of Altana where he was responsible for the successful growth of the company’s UK and Irish operations. He has served as General Manager for Schering-Plough, Portugal, and in a variety of senior management roles for Sanofi-Aventis (formerly Sanofi Synthelabo), Reckitt & Colman and Rhone Poulenc Rorer.

Mr. Jungles joined BioMarin in June 1999 and currently serves as vice president of supply chain. His responsibilities include oversight of planning, warehousing, manufacturing support, contract manufacturing and distribution functions for the company's clinical and commercial products. Prior to coming to BioMarin, Mr. Jungles served as Associate Director of Manufacturing and Operations at the Harvard Gene Therapy Initiative, where he was responsible for the clinical manufacturing of recombinant viral vectors and the supervision of Manufacturing, Quality Control, Quality Assurance, Operations and support staff. From 1993 to 1997, Mr. Jungles acted as manager of process development and clinical production at Somatix Therapy Corporation and oversaw process development and large scale cGMP production of cellular vaccines. Earlier in his career, he was involved in process development-related positions at Hygeia Pharmaceuticals, Inc., and the Hyland Division of Baxter. Mr. Jungles received a B.S. in Biology from the University of Iowa and holds a California State Board of Pharmacy Exemptee Certificate for the manufacture of dangerous drugs.

Dr. Sluzky joined BioMarin in February 2003 and currently serves as vice president of Quality and Analytical Chemistry. Her responsibilities include oversight of Quality Control, Quality Assurance, Validation and Analytical Chemistry groups. Prior to coming to BioMarin, Dr. Sluzky was Director of Analytical and Formulation Development at Onyx Pharmaceuticals, where she was responsible for developing in-process, characterization and stability assays for recombinant adenoviruses, as well as managing formulation development efforts. From 1992 to 1999, Dr. Sluzky was involved in pharmaceutical research and development for various biotechnology products ranging from small molecules and peptides to proteins, first at Scios and then at COR Therapeutics (now Millennium Pharmaceuticals). Dr. Sluzky has contributed to numerous regulatory submissions and peer reviewed publications. She holds a Ph.D. in Chemical Engineering from MIT and a B.S. (also in Chemical Engineering) from Stanford University.

Joseph Klein, III , age 46, has served as a Director of Isis since December 2005. Mr. Klein is currently Managing Director of Gauss Capital Advisors, LLC, a financial consulting and investment advisory firm focused on biopharmaceuticals, which he founded in March 1998. In addition to his investment advisory and financial consulting activities, Mr. Klein currently serves as a Venture Partner of Red Abbey Venture Partners, LP, a life sciences private equity fund. From September 2001 to September 2002, Mr. Klein was a Venture Partner of MPM Capital, a healthcare venture capital firm. From June 1999 to September 2000 when it merged with WebMD Corporation, Mr. Klein served as Vice President, Strategy for Medical Manager Corporation, a leading developer of physician office management information systems. Mr. Klein serves on the board of directors of four publicly held biotechnology companies: BioMarin Pharmaceutical Inc. since June 2005; NPS Pharmaceuticals, Inc. since 1998, but does not intend to stand for reelection to NPS board at its annual meeting in May 2007; OSI Pharmaceuticals, Inc. since July 2006; and Savient Pharmaceuticals, Inc. since May 2006.

Louis Drapeau joined InSite Vision in October 2007. Prior to InSite Vision, he served as Chief Financial Officer, Senior Vice President, Finance, at Nektar Therapeutics, a biopharmaceutical company headquartered in San Carlos, California. Prior to Nektar, he served as Acting Chief Executive Officer from August 2004 to May 2005 and as Senior Vice President and Chief Financial Officer from August 2002 to August 2005 for BioMarin Pharmaceutical Inc. Previously, Drapeau spent 30 years at Arthur Andersen including 19 years as an Audit Partner in Arthur Andersen?s Northern California Audit and Business Consulting practice which included 12 years as Managing Partner. Drapeau received both his undergraduate degree in mechanical engineering and a Masters in Business Administration from Stanford University. He serves as a Director of Bio-Rad Laboratories, InterMune, Inc., BioNovo Inc. and Inflazyme Pharmaceuticals Ltd.

Mike has 30 years of experience in the biopharmaceutical industry and is currently President and CEO of SGX Pharmaceuticals (formerly Structural GenomiX). Prior to joining SGX in 2001, Mike served as President and CEO of Trega Biosciences until its acquisition by Lion Bioscience. He also served as President of BioChem Therapeutics, a subsidiary of BioChem Pharma, from 1994 to 1998. From 1974 to 1993, Mike served in various roles with Glaxo Holdings plc and Glaxo Inc., including positions as Vice President, Corporate Development, and Director, International Licensing. Mike currently serves on the board of directors of Achillion Pharmaceuticals and IDM Pharma (formerly known as Epimmune).

Mr. Meier joined the BioMarin Board in December 2006. Mr. Meier is currently an executive at Advanced Medical Optics, where he served as the Chief Operating Officer and Chief Financial Officer from January 2007. From April 2006 to February 2007, he was Advanced Medical Optics' Executive Vice President, of Operations and Chief Financial Officer, and from April 2002 to February 2004, Mr. Meier was Corporate Vice President and Chief Financial Officer. Prior to joining Advanced Medical Optics, Mr. Meier was the Executive Vice President and Chief Financial Officer of Valeant Pharmaceuticals, Inc., from January 2000, and Senior Vice President & Treasurer from May 1998 to January 2000. Before joining Valeant, Mr. Meier was an executive with the investment banking firm of Schroder & Co. Inc. in New York, from 1996. Prior to Mr. Meier's experience at Schroder & Co., he held various financial and banking positions at Soloman Smith Barney, Manufacturers Hanover Corporation, Australian Capital Equity, and Greyhound Lines, Inc.

Vijay B. Samant joined us as President and Chief Executive Officer in November 2000. Previously, he held various positions at Merck, from 1977 to 2000. From 1998 to 2000, he was Chief Operating Officer of the Merck Vaccine Division. From 1990 to 1998, he served in the Merck Manufacturing Division as Vice President of Vaccine Operations, Vice President of Business Affairs and Executive Director of Materials Management. From 1977 to 1990, Mr. Samant held a variety of positions of increasing responsibility in manufacturing, process engineering, production planning and control, business development and loss prevention in several Merck operating divisions. Mr. Samant holds a bachelor s degree in chemical engineering from the University of Bombay, India, an M.S. degree in chemical engineering from Columbia University and an M.B.A. degree from the Sloan School of Management at the Massachusetts Institute of Technology. Mr. Samant is a director of the Aeras Global TB Vaccine Foundation, a not-for-profit organization working to develop tuberculosis vaccines, serves on the Project Management Subcommittee of the International AIDS Vaccine Initiative and is on the Board of Trustees of the National Foundation for Infectious Diseases and the International Vaccine Institute in Seoul, South Korea.